Table 3.

In-hospital and 1-year clinical outcome.

	Group 1(*1/*1) n = 1682	Group 2 (*1/*R) n = 2171	Group 3 (*R/*R) n = 636	p-value
In-hospital mortality, n (%)	1 (0.1)	0 (0)	2 (0.3)	0.15
1-year clinical events
Primary endpoints
All death, n (%)	25 (1.5)	41 (1.9)	19 (3.0)	0.03
Cardiac death, n (%)	12 (0.7)	30 (1.4)	13 (2.0)	0.01
Non-fatal MI, n (%)	16 (1.0)	25 (1.2)	7 (1.1)	0.64
Secondary endpoints
Stent thrombosis†, n (%)	2 (0.1)	9 (0.4)	4 (0.6)	0.04
Ischemic stroke, n (%)	10 (0.6)	11 (0.5)	4 (0.6)	0.96
Repeat revascularisation, n (%)	121 (7.2)	151 (7.0)	42 (6.6)	0.62
MATE‡, n (%)	38 (2.3)	68 (3.1)	21 (3.3)	0.10
Bleeding§, n (%)	33 (2.0)	38 (1.8)	15 (2.4)	0.74
Any transfusion, n (%)	53 (3.2)	63 (2.9)	24 (3.8)	0.65

*Data were presented as n (%). Abbreviations: MI, myocardial infarction; MATE, major adverse thrombotic event. *R represents *2 or *3.

^†Stent thrombosis included definite or possible stent thrombosis according to ARC criteria.

^‡MATE, defined as the composite of cardiac death, non-fatal MI, stent thrombosis, and ischemic stroke.

^§Bleeding was defined as a clinical bleeding event acceptable for BARC classification type 3, 4, or 5.